TRxADE HEALTH, Inc.
MEDS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.14 | 0.03 | 0.00 |
| FCF Yield | -2.45% | -2.09% | -9.07% | -8.26% |
| EV / EBITDA | -73.93 | -15.10 | -11.05 | 1.34 |
| Quality | ||||
| ROIC | -3.63% | -6.81% | -3.03% | -8.85% |
| Gross Margin | 97.39% | 0.00% | 6.56% | 20.96% |
| Cash Conversion Ratio | 0.89 | 0.30 | 0.96 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -58.42% | -76.13% | -75.87% | -77.15% |
| Free Cash Flow Growth | -57.09% | 30.92% | -53.16% | 64.25% |
| Safety | ||||
| Net Debt / EBITDA | -0.93 | -0.53 | -0.41 | 0.14 |
| Interest Coverage | -2.00 | -10.28 | -4.57 | 5.00 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19,956.89 | 0.00 | 5,607.38 | 817.81 |